SEC Form 4 Filing for Pierre Sayad

Pierre Sayad, Chief Medical Officer of FENNEC PHARMACEUTICALS INC., reported a transaction on 2026-09-30 involving 168 common shares acquired at no cost. This acquisition, marked by transaction code "A", resulted in a post-transaction shareholding of 9,687 shares. The shares were released from restriction, as indicated by footnote F1, originating from an award on March 28, 2025. The filing, designated as document type "4", was signed by Sayad on October 1, 2026.